Cipla Limited (NSE:CIPLA)
1,477.00
-9.80 (-0.66%)
May 9, 2025, 3:30 PM IST
Cipla Revenue
Cipla had revenue of 69.62B INR in the quarter ending December 31, 2024, with 7.01% growth. This brings the company's revenue in the last twelve months to 267.20B, up 6.39% year-over-year. In the fiscal year ending March 31, 2024, Cipla had annual revenue of 255.37B with 13.20% growth.
Revenue (ttm)
267.20B
Revenue Growth
+6.39%
P/S Ratio
4.49
Revenue / Employee
9.62M
Employees
27,764
Market Cap
1,200.80B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
Mar 31, 2020 | 170.81B | 7.57B | 4.64% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Apollo Hospitals Enterprise | 211.46B |
Mankind Pharma | 116.41B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Fortis Healthcare | 75.61B |
Cipla News
- 21 days ago - Cipla’s Goa unit gets ‘Voluntary Action Indicated’ classification from USFDA after inspection - Business Upturn
- 4 weeks ago - Cipla in focus after USFDA approves generic version of blockbuster cancer drug Abraxane - Business Upturn
- 4 weeks ago - Cipla receives USFDA approval for Generic Abraxane - Business Upturn
- 4 weeks ago - Pharma Stocks Falls: Aurobindo Pharma slips 2%, Lupin down 2%, Divi’s Labs falls 3% as Trump reiterates tariffs on pharmaceuticals ‘soon’ - Business Upturn
- 4 weeks ago - Cipla: Business Model, Q3 FY25 Earnings, Promoter Details, and Shareholding Pattern - Business Upturn
- 5 weeks ago - Nifty 50 top losers today, April 4: Tata Steel, Hindalco Industries, ONGC, Tata Motors, Cipla and more - Business Upturn
- 5 weeks ago - Cipla shares drop over 6% after Trump hints at pharma tariffs; heavy U.S. exposure adds pressure - Business Upturn
- 5 weeks ago - Nifty 50 top gainers today, April 3: Power Grid, Sun Pharmaceutical, Cipla, UltraTech and more - Business Upturn